“Growing Shift Toward Non-Invasive and Uterus-Preserving Treatment Options”
- One prominent trend in the Uterine Fibroids market is the growing shift toward non-invasive and uterus-preserving treatment options
- This trend is driven by increasing patient demand for fertility preservation, shorter recovery periods, and reduced surgical risks compared to traditional hysterectomy
- For instance, in 2022, the U.S. FDA approved the Exablate 2100 system by Insightec for MR-guided focused ultrasound (MRgFUS), enabling non-invasive treatment of uterine fibroids with real-time imaging and no incisions
- This development is transforming fibroid management by offering effective, outpatient-based treatment options that preserve the uterus and improve quality of life for women
- The Uterine Fibroids market is expected to grow steadily, supported by rising adoption of non-surgical alternatives, technological advancements, and increasing awareness of reproductive health and minimally invasive solutions
